A local hospital is using new technology to remove liver cancer without invasive surgery. It’s a word that no one ever wants ...
Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
News Nation on MSN
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA
Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...
PEABODY, Mass., Nov. 17, 2025 /PRNewswire/ -- Privo Technologies today announced results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch for ...
Histotripsy is a non-invasive treatment, approved by the Food and Drug Administration (FDA) in 2023, that uses ultrasound energy to destroy liver tumors in a single outpatient procedure. This includes ...
Hosted on MSN
What If Some Breast Cancers Aren't Really Cancer?
Ductal carcinoma in situ (DCIS) is a non-invasive breast condition found in nearly 20% of breast cancer diagnoses, but a growing number of doctors and medical experts are questioning whether the term ...
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
We combine affordable thermal cameras with advanced AI to analyse temperature maps of the human body without radiation, ...
Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback